NEW YORK, July 8, 2015 – Precision for Value (www.precisionforvalue.com), a Precision for Medicine Company which provides health economics, analytics, and marketing communications services to life sciences clients, today announced the further expansion of its Health Economics and Outcomes Research (HEOR) team to meet growing customer demand. Christopher Blanchette, PhD, was appointed Vice President, Health Economics.

(more…)

Los Angeles, CA, April 27, 2015—Precision Health Economics (PHE), a Precision for Medicine company, announced today the hiring of James Baumgardner, PhD, as Senior Research Economist. Joining PHE from his post as Deputy Assistant Director in the Health, Retirement, and Long-Term Analysis Division of the Congressional Budget Office (CBO), Mr. Baumgardner brings unique experiences and perspectives to the complex and challenging problems PHE addresses in its work on health economics and policy. PHE is focused on the critical issues in health and healthcare delivery: objective determination of value and measureable improvement in patient outcomes.

(more…)

Extends Leadership in Health Economics and Outcomes Research With a Focus on Evidence Generation in an Era of Precision Medicine

Bethesda, MD, and Los Angeles, April 16, 2015 – Precision for Medicine (Precision), a specialized services company supporting next-generation approaches to drug development and commercialization, today announced the acquisition of Precision Health Economics (PHE). A world-renowned and cutting-edge health economics consultancy and analytics firm, PHE leverages the expertise of policy analysts, economists, clinicians, and academics to advance research on the most complex healthcare questions. Life sciences companies and policymakers worldwide turn to PHE to shape strategy, inform key healthcare decisions, and produce effective changes in policy through innovative research.

(more…)

BETHESDA, MD – March 26, 2015 – Precision for Medicine (www.precisionformedicine.com) today announced the PATH™ analytics platform, a unique tool that can identify, analyze, and provide novel scientific insights about important biomarkers, transforming traditional therapies into personalized therapeutics. PATH™ accelerates the research process, enabling a more streamlined framework for stratifying patient populations.

(more…)

(BETHESDA, MD) Nov. 4, 2014 – Precision for Medicine announced today that its subsidiary, Precision Bioservices, Inc., has been awarded a 7-year contract of up to $28 million to provide management and oversight of disease-study specimens for the National Institute of Allergy and Infectious Diseases (NIAID). NIAID is part of the National Institutes of Health (NIH), an agency of the US Department of Health and Human Services.

(more…)

(BETHESDA, MD) March 25, 2014 – Precision for Medicine, Inc., formed in 2012 to support next generation approaches to drug development and commercialization, announces the acquisition of Hobart Group Holdings, LLC (Hobart), a leading market access firm. With this addition, Precision for Medicine (Precision) has established the foundation for its next phase of growth in providing integrated solutions focused on demonstrating value in the era of precision medicine.

(more…)

Industry Expert in Regulatory Sciences and Commercial Strategy Joins New Service Organization Focused on Helping Life Science Companies Develop and Commercialize Next-Generation Medical Products

(Bethesda, MD) April 8, 2013 – Precision for Medicine, Inc., (“Precision”) today announced that Karen Becker, PhD, has joined the company’s leadership team and will help life science companies capitalize on next-generation approaches to product development and commercialization.

(more…)

(Bethesda, MD) April 2, 2013 – Precision for Medicine, Inc., formed in 2012 to support next-generation approaches to drug development and commercialization, today announced that it has secured $150 million in private equity financing to support acquisitions and development. Precision for Medicine is building a comprehensive platform of specialized development and commercialization services to support life science companies that are seeking to capitalize on the benefits of patient-centered, precision medicine. Oak Investment Partners, J.H. Whitney and Company, and LCI Capital led the financing.

Ethan D. Leder and Mark P. Clein, co-founders of the Maryland-based company, said the funding will be used to acquire the expertise and infrastructure necessary to guide innovative medical products from discovery to patients.

(more…)

Industry Experts Will Support the Development and Commercialization of Medical Diagnostic and Device Products, Including Companion Diagnostics for Next-Generation Medicines

(Bethesda, MD) May 17, 2013 – Precision for Medicine, Inc., (“Precision”), the specialized scientific services company formed in 2012 to support next-generation medical products, today announced the appointment of 4 key executives, significantly increasing the breadth of its regulatory and commercialization services. The addition of these executives and their teams enhances Precision’s ability to support life science innovators as they address value, effectiveness, and patient access issues for next generation medicines.

(more…)